
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions regarding Eden Research Plc have been notably charged, with significant skepticism surrounding the company's long-term profitability and current valuation. Many participants expressed frustration over Eden's failure to turn a profit in its thirty-year existence, with one user provocatively inquiring about the terminology of "investor" in such a scenario, stating, "Just for a laugh then, what do YOU call someone who puts money into a company that has has existed for thirty years, but has not yet even once returned a profit?" This sentiment underscores a prevailing lack of confidence in Eden's financial trajectory, particularly as discussions hinted at ongoing cash flow challenges and potential dilution concerns.
Amidst the skepticism, there were some discussions of recent developments, including updates on product pipelines and regulatory progress. Noteworthy was the mention of the company’s impending launch of an insecticide projected for 2025 in the U.S. and EU. However, clarity surrounding the revenues from upcoming products like Ecovolex remained elusive. Participants frequently noted the need for the company to demonstrate its ability to generate revenue to regain investor trust, with comments reflecting a cautious stance towards future fundraising efforts. As one user aptly summarized, "For most an opportunity for Eden to reset previous estimations and elaborate on future fundraising."
Overall, investor sentiment appears to be firmly anchored in skepticism, characterized by a blend of critical commentary and a desire for clearer communication around product viability and business strategy. The discussions indicate a cautious wait-and-see approach as investors grapple with the dichotomy of potential regulatory approvals against a history of disappointing performance.
Show more
Eden Research Plc, a company focused on sustainable biopesticide and biocontrol technology, has reported significant developments in its leadership's shareholding activity. On February 6, 2025, Lykele van der Broek, the Non-Executive Chairman, purchased 256,000 ordinary shares at a price of 3.90 pence each. This acquisition brought his total shareholding to 1,877,808 shares, representing 0.35% of the company's issued capital. Earlier, on January 28, several directors, including CEO Sean Smith and CFO Alex Abrey, collectively acquired over 1.4 million shares at an average price of 3.68 pence each, underscoring a robust commitment from management to increase their stake in the company.
Additionally, Eden Research is engaging with investors through live presentations. Scheduled for February 13, 2025, CEO Sean Smith and CFO Alex Abrey will address existing and potential shareholders via the Investor Meet Company platform, allowing for an interactive Q&A format. This initiative highlights the company's transparency and willingness to foster dialogue with its investor community, aiming to bolster confidence and attract further interest as it advances its sustainable agricultural solutions.
Show more
Just for a laugh then, exactly who is it that is paying me and how much? You claim to know everything? |
The share price chsrt heeds me. |
You are just wasting your time, and internet bandwidth. No one cares for your posts, lies or threats. Nothing has ever come of them. The FSA are doing absolutely jack sheet about your threats of legal action, not that they are warranted in the first place. |
lol and ssshhhhhh, ijjit. There's a reason you never took an IQ test. |
My most recent article prompted an intriguing response from a brand-new avatar. |
To anyone interested in market value projections for 2024 to 2030F. Here’s the latest update on market value projections (Net Sales), incorporating recent financial results from industry leaders: FMC and Corteva. |
"we know there are people on this call who are new to the story" |
Kitty, |
It is my understanding you cannot apply for a label extension when you have not yet been granted a label. |
It is usually two years of testing, all things being equal, is it not. If those trials started in 2023 then in theory, those trials could be complete with an answer due. If those trials are complete, have Eden and Corteva sought a label extension already? |
Not included in the Ecovelex revenue calculation I presume assuming the trials went well. |
Nevertheless might add a few next week |
Super, |
So cash will be needed as 5.2 is quite tidgy in the wider scheme of things,.That reads pretty categorically . It's for debate but the reset seems to me the fizz comes later than 2025. "No current plans"Bit like DE Gaulle saying he understood Algeria and then knocking ten bells out of the place. |
Looks to me like yesterdays presentation was an unofficial Eden Reset. |
Alchemy 14 Feb '25 - 15:26 - 19965 |
SHUT UP YOU LYING RAMPING SCAMMER!!!! |
Type | Ordinary Share |
Share ISIN | GB0001646941 |
Sector | Biological Pds,ex Diagnstics |
Bid Price | 3.70 |
Offer Price | 3.90 |
Open | 3.85 |
Shares Traded | 420,004 |
Last Trade | 13:16:44 |
Low - High | 3.80 - 3.85 |
Turnover | 3.19M |
Profit | -6.49M |
EPS - Basic | -0.0122 |
PE Ratio | -3.11 |
Market Cap | 20.53M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions